Organogenesis to discuss Q1 results and corporate update May 7
Organogenesis Holdings Inc. (Nasdaq: ORGO) will report its first-quarter fiscal year 2026 financial results after market close on May 7, 2026. The company will host a conference call and live webcast at 5:00 p.m. Eastern Time on the same day to discuss the results and provide a corporate update with a question-and-answer session. This announcement follows a strong fiscal year 2025 with record net product revenue, and investors will be looking for how Q1 2026 trends align with the company's fiscal 2026 revenue guidance of $350M–$420M.
ORGO SEC Filings - Organogenesis Hldgs Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Organogenesis Holdings Inc. (ORGO) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It offers direct access to regulatory disclosures, financial statements, and updates on clinical programs and governance matters. Recent filings detail equity grants to directors and a vice president, with restricted stock units and options vesting in 2027 and shares withheld for taxes.
Director at Organogenesis (NASDAQ: ORGO) purchases 5,000 shares
Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an open-market purchase of 5,000 shares of Class A common stock at $2.681 per share on March 9, 2026. This transaction increased his directly held stake to 291,014 shares. The purchase, detailed in an SEC Form 4 filing, is a positive signal highlighting an additional personal capital commitment by the director.
Organogenesis (ORGO) director adds 10,000 shares in open-market purchase
Organogenesis Holdings Inc. director Michael Joseph Driscoll purchased 10,000 shares of Class A Common Stock in an open-market transaction on March 9, 2026. He bought the shares at approximately $2.67 per share, totaling around $26,688. This purchase increases his direct ownership to 225,707 shares, representing a relatively small but positive addition to his stake.
Organogenesis director Leibowitz buys $13k in ORGO stock
Arthur S. Leibowitz, a director at Organogenesis Holdings Inc (NASDAQ:ORGO), purchased 5,000 shares of Class A Common Stock for $13,405. This insider buying occurred as ORGO stock trades near its 52-week low, and an InvestingPro analysis suggests the stock is undervalued and in oversold territory. The company recently reported strong Q4 2025 financial results, exceeding EPS and revenue expectations, despite broader market concerns about regulatory changes and competitive pressures.
Organogenesis director Leibowitz buys $13k in ORGO stock
Arthur S. Leibowitz, a director at Organogenesis Holdings Inc (NASDAQ:ORGO), recently purchased 5,000 shares of Class A Common Stock for over $13,000, bringing his total direct ownership to 291,014 shares. This insider buying activity occurred with ORGO stock trading near its 52-week low and shares down 49% over the past year, despite the company reporting strong Q4 2025 financial results with earnings and revenue surpassing expectations.
Organogenesis (ORGO) VP uses 700 shares to cover tax withholding
Organogenesis Holdings Inc.'s VP of Strategy, Robert Cavorsi, reported a tax-related transfer of 700 Class A common stock shares at $3.21 each to cover tax withholding obligations. This transaction leaves him with 275,524 direct shares. This was not a traditional buy or sell but a disposition to satisfy tax liabilities tied to equity awards.
[Form 4/A] Organogenesis Holdings Inc. Amended Insider Trading Activity
This article reports on an amended insider trading activity for Organogenesis Holdings Inc. (ORGO). The company's Chief Financial Officer, Francisco David, filed an amended Form 4 correcting the share counts for an equity award vesting and related tax withholding, which occurred on February 18, 2026. The amendment clarified that 44,040 shares of Class A common stock were acquired as a grant at no cost, and 14,687 shares were withheld to cover tax obligations.
[Form 4/A] Organogenesis Holdings Inc. Amended Insider Trading Activity
Organogenesis Holdings Inc.'s Chief Operating Officer, Patrick Bilbo, filed an amended Form 4 to correct previously reported insider trading activity. The amendment clarifies the number of Class A Common Stock shares acquired from a vested performance award and the associated tax withholding. Following these corrections, Bilbo now holds 1,128,312 shares of Class A Common Stock.
Organogenesis (ORGO) VP updates Form 4 for award vesting and tax shares
Organogenesis Holdings Inc.'s VP of Strategy, Robert Cavorsi, filed an amended Form 4 to correct details regarding a performance share award. The filing clarifies the number of Class A Common Stock shares acquired upon vesting (16,454) and shares withheld for tax obligations (5,487 at $3.84 per share). Following these adjustments, Cavorsi's direct holdings now total 276,224 Class A shares, with no other changes made to the original report.
ORGO (Organogenesis) CEO amends Form 4 for stock grant and tax share disposal
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney has amended his Form 4 filing to correct previously reported equity compensation activity. The amendment clarifies that he acquired 188,856 shares of Class A common stock as a grant and disposed of 91,311 shares to cover tax obligations, with no other changes made to the original Form 4. This update adjusts the numbers for a performance share vesting and related tax-withholding.
Organogenesis (NASDAQ: ORGO) officer amends Form 4 for award and tax-withheld shares
Organogenesis Holdings Inc. Chief Administrative and Legal Officer, Lori Freedman, filed an amended Form 4 to correct previously reported figures regarding her insider holdings. The amendment clarifies that she acquired 43,212 shares of Class A common stock from a performance share award at no cost, and 14,411 shares were withheld to cover associated tax obligations. This filing updates only the share amounts for the award and tax-withheld shares, with all other details from the original filing remaining unchanged.
Organogenesis (ORGO) CCO corrects insider grant and tax-share amounts
Organogenesis Holdings Inc.'s Chief Commercial Officer, Brian Grow, filed an amended insider transaction report (Form 4/A) to correct previously reported share amounts. The amendment specifies that on February 18, 2026, Grow acquired 48,818 shares through a performance share award and disposed of 11,887 shares at $3.84 each to cover tax obligations, resulting in a corrected direct ownership of 899,724 shares. The filing clarifies that only the share figures were amended, with no other changes to the original report.
Organogenesis Holdings (ORGO) Margin-Driven Profitability Shift Tests Revenue Concern Narratives
Organogenesis Holdings (ORGO) reported strong Q4 2025 results with US$225.6 million in revenue and US$0.28 EPS, indicating a shift towards margin-driven profitability. While bulls highlight rapid earnings growth and a positive turn in trailing twelve-month EPS, bears point to projected revenue declines and segment pressures as potential challenges to sustained profitability. The company's P/E ratio is below industry averages, suggesting that the market has not fully priced in future earnings expectations despite recent gains.
Organogenesis (ORGO) CAO files Form 3 detailing stock and RSUs
Organogenesis Holdings Inc.'s Chief Accounting Officer, Patrick McGuire, filed an initial ownership statement (Form 3) detailing his direct holdings of Class A common stock and restricted stock units (RSUs). The filing specifies that the RSUs were granted under the 2018 Equity Incentive Plan and have various vesting schedules extending into late 2026, 2027, 2028, and early 2029. This document provides transparency regarding McGuire's initial beneficial ownership in the company.
Organogenesis Holdings Q4 Earnings Report: What Investors Need to Know
Organogenesis Holdings (NASDAQ: ORGO) reported its Q4 earnings, beating estimated EPS by 90.48% with an EPS of $0.4 compared to an estimate of $0.21. Revenue was up $98.95 million year-over-year. This positive report follows a consistent trend of the company surpassing EPS estimates in previous quarters.
Organogenesis Holdings Inc. (ORGO) Stock Rises on Q4 2025 Earnings
Organogenesis Holdings Inc. (ORGO) reported strong Q4 2025 earnings, with revenue increasing by 78.1% year-over-year to $225.6 million, significantly beating analyst estimates. This performance led to a 2.7% rise in the stock price. The article also details insider trading activity, institutional holdings changes, government contracts, and analyst ratings for ORGO.
Organogenesis (NASDAQ: ORGO) CFO uses share dispositions to cover taxes
Organogenesis Holdings Inc. CFO Francisco David reported four tax-withholding dispositions of Class A common stock on February 15, 2026, at $3.73 per share. These transactions, coded 'F' on Form 4, represent the use of existing shares to cover tax obligations rather than open-market sales. After these dispositions, David directly owns 506,647 Class A common shares.
Organogenesis Holdings (NASDAQ: ORGO) COO gets new stock and option awards
Organogenesis Holdings Inc.'s Chief Operating Officer, Patrick Bilbo, received new equity awards including a stock option for 120,267 Class A common shares and 259,549 Class A shares through stock awards on February 18, 2026. These awards include restricted stock units and performance shares that vest over four years. Bilbo also disposed of 16,212 shares to cover tax obligations related to these new grants and vesting events.
[Form 4] Organogenesis Holdings Inc. Insider Trading Activity
Organogenesis Holdings Inc.'s Vice President of Strategy, Robert Cavorsi, reported three tax-withholding dispositions of Class A Common Stock. These transactions on February 15, 2026, involved delivering shares at $3.73 each to cover tax obligations related to equity compensation. After these dispositions, Cavorsi retained a substantial direct stake in the company.
Equity grant gives Organogenesis (ORGO) director 48,828 RSUs vesting 2027
Organogenesis Holdings Inc. director Michael Joseph Driscoll received an equity grant of 48,828 restricted stock units (RSUs) of Class A common stock. This compensation-related acquisition, granted at no cash cost, will vest in full on February 15, 2027. Following the grant, Driscoll's direct Class A share balance stands at 215,707 shares.
Organogenesis (ORGO) CCO receives stock awards, with shares withheld for taxes
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow received new equity awards, including a stock option for 133,630 shares and Class A common stock from restricted stock units and a performance share award. Concurrently, 11,768 shares were disposed of at $3.84 each to cover tax withholding obligations related to a performance award. Following these transactions, Grow directly holds 899,355 shares of Organogenesis Class A common stock.
Executive equity awards at Organogenesis (ORGO) include RSUs, options and tax withholding
Organogenesis Holdings Inc. Vice President Robert Cavorsi received multiple equity awards, including stock options for 53,452 shares and 110,040 shares of Class A common stock, which include restricted stock units and performance-based shares. These awards vest over four years, with some shares tied to 2025 performance milestones. A total of 5,432 shares were withheld to cover tax obligations at $3.84 per share, indicating routine equity compensation rather than open-market trading.
Director at Organogenesis (ORGO) receives 48,828 restricted stock units
Organogenesis Holdings Inc. director Garrett Lustig was awarded 48,828 restricted stock units (RSUs) of Class A common stock, increasing his direct holdings to 125,742 shares. The RSUs, granted at $0.00 per share, vest in full on February 15, 2027, aligning his compensation with the company's long-term performance. This transaction was reported via SEC Form 4 and is considered a neutral event for the company's stock.
Organogenesis Holdings (NASDAQ: ORGO) officer disposes shares for taxes
Organogenesis Holdings Inc.'s Chief Administrative and Legal Officer, Lori Freedman, disposed of shares to cover tax liabilities on February 15, 2026. She carried out four transactions, delivering a total of 54,742 Class A common shares at a price of $3.73 per share to satisfy tax obligations. After these non-market transactions, Freedman directly holds 791,717 shares.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP has launched an investigation into Organogenesis Holdings Inc. (NASDAQ: ORGO) following a significant stock price drop. The investigation concerns potential securities fraud after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations related to skin substitute products, which analysts believe will increase competition for Organogenesis and led to a 10.14% decline in its stock. Investors affected by these events are encouraged to contact Pomerantz LLP for more information about joining a potential class action.
Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?
Organogenesis Holdings (NASDAQ:ORGO) is analyzed for its growth prospects, focusing on its cash burn rate and cash runway. The company has a cash runway of approximately 15 months based on its September 2025 balance sheet and burned US$52m in the past year. Despite minimal revenue growth of 2.1%, its cash burn of US$52m represents a low 9.7% of its US$534m market capitalization, suggesting it could likely raise additional funds if needed without significant dilution.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential claims of securities fraud or other unlawful business practices against Organogenesis Holdings Inc. (NASDAQ: ORGO) and its officers. This investigation follows a 10.14% drop in Organogenesis's stock price after the Centers for Medicare & Medicaid Services withdrew final Local Coverage Determinations related to skin substitute grafts, which analysts believe will increase competition for the company. Investors are encouraged to contact Pomerantz LLP for more information regarding potential class action involvement.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.
Pomerantz LLP is investigating Organogenesis Holdings Inc. (ORGO) on behalf of investors following a significant stock price drop. The investigation stems from the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations related to skin substitute products, which analysts believe will increase competition for Organogenesis and led to a 10.14% stock decline on December 30, 2025. The firm is examining potential securities fraud or unlawful business practices by the company's officers and directors.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (ORGO) after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations related to skin substitute grafts. This withdrawal is expected to increase competition for Organogenesis, leading to a 10.14% drop in its stock price. Investors are encouraged to contact Pomerantz LLP for information regarding a potential class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (NASDAQ: ORGO) following a significant stock price drop. The investigation commenced after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations related to skin substitute products, which analysts believe will increase competition for Organogenesis. This development led to a 10.14% fall in Organogenesis's stock price on December 30, 2025.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (NASDAQ: ORGO) on behalf of investors. This investigation follows the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations (LCDs) related to skin substitute grafts, which analysts believe will increase competition for Organogenesis. The company's stock subsequently fell by 10.14% on December 30, 2025, after this news.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating Organogenesis Holdings Inc. (NASDAQ: ORGO) following a significant stock price drop. The investigation concerns potential securities fraud after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations related to skin substitute products, increasing competition for Organogenesis and leading to a 10.14% decline in its stock. Investors are encouraged to contact Pomerantz LLP for information regarding potential class action involvement.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (NASDAQ: ORGO) following a significant 10.14% stock price drop on December 30, 2025. This decline occurred after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations, leading analysts to predict increased competition for Organogenesis. Investors who suffered losses are advised to contact Pomerantz LLP for more information regarding a potential class action lawsuit.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (NASDAQ: ORGO) on behalf of investors. The investigation follows a 10.14% drop in Organogenesis's stock price after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations, which analysts predict will increase competition for the company. Investors are encouraged to contact Pomerantz LLP for more information regarding the class action investigation.
Organogenesis Holdings extends leases for Canton facilities through 2032 By Investing.com
Organogenesis Holdings Inc. announced the extension of lease agreements for two facilities in Canton, Massachusetts, through December 31, 2032, with an option for renewal until 2034. These facilities are crucial for the company's manufacturing, operations, and research and development activities. The lease amendments were approved by the Audit Committee, considering that some major stockholders indirectly own the properties.
Organogenesis Holdings extends leases for Canton facilities through 2032
Organogenesis Holdings Inc. has extended the leases for its Canton, Massachusetts headquarters facilities through 2032, with an option for an additional two-year renewal. The lease amendments involved properties owned by significant shareholders and board members, and were approved by the Audit Committee. This news follows other recent developments such as a rolling Biologics License Application submission for its ReNu product and maintained analyst ratings.
Organogenesis Holdings extends leases for Canton facilities through 2032 By Investing.com
Organogenesis Holdings Inc. announced extensions for the leases of two facilities at its Canton, Massachusetts headquarters through December 31, 2032, with an option for an additional two-year renewal. These facilities are critical for manufacturing, operations, and R&D. The lease amendments, approved by the Audit Committee, involve properties partly owned by significant shareholders of Organogenesis.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. following a significant stock price drop. The investigation began after the Centers for Medicare & Medicaid Services withdrew Local Coverage Determinations related to skin substitute products, which analysts believe will increase competition for Organogenesis. This news led to a 10.14% decline in Organogenesis's stock price on December 30, 2025.
Organogenesis drops as Medicare to pull skin substitute LCDs (update)
Organogenesis (ORGO) and MiMedx (MDXG) shares dropped after the Centers for Medicare & Medicaid Services (CMS) withdrew Local Coverage Determinations (LCDs) related to certain skin substitute products that were set to take effect next year. The withdrawal is expected to increase market competition by allowing over 300 additional products, negatively impacting analyst confidence in Organogenesis's 2026 outlook.
Organogenesis director Nussdorf sells $1.59 million in shares By Investing.com
Organogenesis Holdings Inc. director Glenn H. Nussdorf sold 306,300 shares of Class A Common Stock for $1.59 million across three transactions between November 24 and November 26, 2025. Despite the sales occurring at prices slightly below the current trading price, analysts predict profitability for ORGO this year, with an expected EPS of $0.24 for FY2025. The company recently reported strong Q3 2025 revenue of $150.5 million, exceeding forecasts, and BTIG raised its price target for ORGO to $9.00 due to favorable reimbursement changes in the wound care market.
Organogenesis director Nussdorf sells $1.59 million in shares
Organogenesis Holdings Inc. director Glenn H. Nussdorf sold 306,300 shares of Class A Common Stock for $1.59 million across three transactions between November 24 and November 26, 2025. Despite the sales occurring below the current trading price, analysts expect Organogenesis to be profitable in 2025 with a forecasted EPS of $0.24. The company recently reported strong Q3 2025 revenues of $150.5 million, surpassing analyst forecasts.
Organogenesis Holdings Insider Sold Shares Worth $1,592,120, According to a Recent SEC Filing
An insider at Organogenesis Holdings Inc. (NASDAQ: ORGO) sold shares valued at $1,592,120, as reported in a recent SEC filing. The article highlights this transaction and lists other recent news and financial activities related to the company, including its Q3 2025 earnings and FDA application plans.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organogenesis Holdings Inc. (ORGO) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Organogenesis Holdings Inc. (ORGO) on behalf of investors. This follows a significant drop in Organogenesis's share price after its second Phase 3 ReNu trial failed to meet its primary endpoint for pain reduction. The firm is encouraging shareholders to come forward and assist in the investigation.
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Organogenesis Holdings Inc. announced inducement grants to Michael Catarina, its new Chief Technology Officer. The grants include non-statutory stock options for 82,542 shares and restricted stock units for 47,962 shares of Class A common stock. These awards were made as an inducement for his employment, adhering to Nasdaq Listing Rule 5635(c)(4).
Organogenesis Holdings Inc. Commends CMS on Payment Reform for Skin Substitutes and CTPs Under CY 2026 Fee Schedule | ORGO Stock News
Organogenesis Holdings Inc. has praised the Centers for Medicare & Medicaid Services (CMS) for its payment reform concerning skin substitutes and cellular tissue-based products under the CY 2026 Physician Fee Schedule. CEO Gary S. Gillheeney stated that this new policy, which includes per centimeter square payment and FDA classifications, is expected to enhance access to PMA products and curb existing abuses. The company believes this positions them strongly in the regenerative medicine market for 2026 and beyond.
Organogenesis Holdings Inc. (ORGO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Organogenesis Holdings Inc. (ORGO) after the company announced on September 25, 2025, that its second Phase 3 trial for ReNu failed to meet its primary endpoint, leading to a nearly 12.4% drop in stock price. The law firm is encouraging shareholders who purchased Organogenesis securities to contact them regarding potential claims. They represent investors on a contingency fee basis for securities fraud class actions and shareholder derivative suits.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (NASDAQ: ORGO) after its stock price fell following the disclosure that a second phase 3 trial for its cryopreserved amniotic suspension allograft ReNu failed to meet its primary endpoint. Investors are encouraged to contact the law firm for more information regarding a potential class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. (NASDAQ: ORGO) after the company announced that a phase 3 trial for its ReNu product failed to meet its primary endpoint, leading to a significant drop in its stock price. Investors affected by the stock price decline are encouraged to contact the law firm to learn about potential class action participation.
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
DJS Law Group is investigating Organogenesis Holdings Inc. for potential securities fraud violations. This investigation follows a 12.39% drop in Organogenesis shares on September 26, 2025, after the company announced its ReNu phase 3 trial failed to meet its primary endpoint of pain reduction. Investors who suffered losses are encouraged to contact DJS Law Group to discuss their rights.
